KRAS and cancer: The premetastatic-niche-promoting signature of cancer cell-derived proteins in circulation likely contributes to the previous observation that increased KrasG12D gene dosage (Kras mut-iGD) promotes EMT and metastasis in the mesenchymal PDAC subtype45.